Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Posted by on Nov 2, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL).  This study concluded that this combination was well tolerated and had promising...

Read More

Blinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia

Blinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia

Posted by on Oct 30, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the use of blinatumomab Blincyto; B) or inotuzumab ozogamicin (Besponsa; IO) as a bridge to stem cell transplant for patients with relapsed or refractory (unresponsive) B-cell acute lymphocytic leukemia (B-ALL).  This study concluded that both treatments are safe and effective as a...

Read More

Comparing conditioning treatments for patients with acute myeloid leukemia undergoing stem cell transplant

Comparing conditioning treatments for patients with acute myeloid leukemia undergoing stem cell transplant

Posted by on Oct 28, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate two pre-transplant conditioning regimes for patients with acute myeloid leukemia.  This study concluded that total body irradiation and fludarabine (Fludara) may be a suitable reduced toxicity conditioning treatment option for these patients. Some background A conditioning...

Read More

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Posted by on Oct 25, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma.  This study concluded that this treatment path is feasible and a good alternative for these patients.   Some background Allogenic hemopoietic...

Read More

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if allogeneic stem cell transplantation (allo-SCT) was a safe and effective option for the treatment of patients with chronic lymphocytic leukemia (CLL) after treatment with novel agents (NA).  This study concluded that this treatment option was safe and effective for patients with...

Read More

Cladribine, G-CSF, cytarabine and aclarubicin in patients with relapsed/refractory acute myeloid leukemia 

Cladribine, G-CSF, cytarabine and aclarubicin in patients with relapsed/refractory acute myeloid leukemia 

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of C-CAG including cladribine (Leustatin), granulocyte colony-stimulating factor (G-CSF, Neupogen), cytarabine (Cytosar-U), and aclarubicin (Aclacinon) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML).   This study...

Read More

Comparing chemotherapy-free treatments for patients with treatment naïve chronic lymphocytic leukemia

Comparing chemotherapy-free treatments for patients with treatment naïve chronic lymphocytic leukemia

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate three different chemotherapy-free treatment regimens for patients with chronic lymphocytic leukemia.  This study concluded that acalabrutinib (Calquence) plus obinutuzumab (Gazyva) improved survival without cancer worsening for these patients.   Some background Chemotherapy-free...

Read More

Looking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.

Looking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.

Posted by on Oct 11, 2020 in Leukemia | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the...

Read More